NO20084752L - Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disse - Google Patents
Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disseInfo
- Publication number
- NO20084752L NO20084752L NO20084752A NO20084752A NO20084752L NO 20084752 L NO20084752 L NO 20084752L NO 20084752 A NO20084752 A NO 20084752A NO 20084752 A NO20084752 A NO 20084752A NO 20084752 L NO20084752 L NO 20084752L
- Authority
- NO
- Norway
- Prior art keywords
- aziridinayl
- conjugates
- pharmaceutical compositions
- compositions containing
- epothilone analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80836706P | 2006-05-25 | 2006-05-25 | |
PCT/US2007/069740 WO2007140298A1 (en) | 2006-05-25 | 2007-05-25 | Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084752L true NO20084752L (no) | 2008-12-17 |
Family
ID=38461157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084752A NO20084752L (no) | 2006-05-25 | 2008-11-11 | Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disse |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070275904A1 (ru) |
EP (1) | EP2023960A1 (ru) |
JP (1) | JP2009538350A (ru) |
KR (1) | KR20090025267A (ru) |
CN (1) | CN101495154A (ru) |
AR (1) | AR062448A1 (ru) |
AU (1) | AU2007267536A1 (ru) |
BR (1) | BRPI0712165A2 (ru) |
CA (1) | CA2657276A1 (ru) |
EA (1) | EA200802390A1 (ru) |
IL (1) | IL195237A0 (ru) |
MX (1) | MX2008014788A (ru) |
NO (1) | NO20084752L (ru) |
PE (1) | PE20080102A1 (ru) |
TW (1) | TW200813065A (ru) |
WO (1) | WO2007140298A1 (ru) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE427948T1 (de) * | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
KR20040106547A (ko) * | 2002-05-15 | 2004-12-17 | 엔도사이트, 인코포레이티드 | 비타민-마이토마이신 공액체 |
ES2395082T3 (es) | 2003-01-27 | 2013-02-08 | Endocyte, Inc. | Conjugado de folato-vinblastina como medicamento |
EP1789391B1 (en) | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
EP1863816B1 (en) | 2005-03-16 | 2014-06-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
KR101364912B1 (ko) | 2005-08-19 | 2014-02-21 | 엔도사이트, 인코포레이티드 | 복수-약제 리간드 공액체 |
US20080280937A1 (en) * | 2005-08-19 | 2008-11-13 | Christopher Paul Leamon | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives |
US20100104626A1 (en) * | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
NZ580132A (en) * | 2007-03-14 | 2012-11-30 | Endocyte Inc | Binding ligand linked drug delivery conjugates of tubulysins to vitamins |
CN101754969A (zh) | 2007-05-25 | 2010-06-23 | 百时美施贵宝公司 | 制备埃坡霉素化合物和类似物的方法 |
EP2176293B1 (en) * | 2007-06-25 | 2019-04-03 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
AU2008316835B2 (en) | 2007-10-25 | 2015-07-16 | Endocyte, Inc. | Tubulysins and processes for preparing |
BR112013026680A2 (pt) * | 2011-08-15 | 2016-12-27 | Univ City New York Res Found | composto, método de tratamento de uma doença inflamatória e composição farmacêutica |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
KR20150070318A (ko) | 2012-10-16 | 2015-06-24 | 엔도사이트, 인코포레이티드 | 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법 |
US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
WO2014101134A1 (zh) * | 2012-12-28 | 2014-07-03 | Yan Wenguang | 叶酸衍生物及其制备方法和应用 |
CN104784699B (zh) * | 2014-01-20 | 2019-05-03 | 博瑞生物医药(苏州)股份有限公司 | 叶酸受体结合配体-药物偶联物 |
EP3119803B1 (en) | 2014-03-20 | 2019-09-11 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
CN113929770A (zh) | 2014-11-21 | 2022-01-14 | 百时美施贵宝公司 | 包含修饰的重链恒定区的抗体 |
PL3221363T3 (pl) | 2014-11-21 | 2021-01-11 | Bristol-Myers Squibb Company | Przeciwciała przeciwko cd73 i ich zastosowanie |
EA037590B1 (ru) | 2014-11-25 | 2021-04-19 | Бристол-Майерс Сквибб Компани | Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации |
WO2016144608A1 (en) | 2015-03-10 | 2016-09-15 | Bristol-Myers Squibb Company | Antibodies conjugatable by transglutaminase and conjugates made therefrom |
RS63897B1 (sr) | 2015-05-29 | 2023-02-28 | Bristol Myers Squibb Co | Antitela protiv ox40 i njihova primena |
US10584160B2 (en) | 2015-09-23 | 2020-03-10 | Bristol-Myers Squibb Company | Glypican-3-binding fibronectin based scaffold molecules |
BR112018007673A2 (pt) | 2015-10-16 | 2018-11-06 | Univ Rice William M | ?análogos de epotilona, métodos de síntese, métodos de tratamento e conjugados de fármaco dos mesmos? |
SG11201805150QA (en) | 2015-12-21 | 2018-07-30 | Bristol Myers Squibb Co | Variant antibodies for site-specific conjugation |
BR112018067368A2 (pt) | 2016-03-04 | 2019-01-15 | Bristol-Myers Squibb Company | terapia de combinação com anticorpos anti-cd73 |
US20190218294A1 (en) | 2016-09-09 | 2019-07-18 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
US20200299400A1 (en) | 2017-05-25 | 2020-09-24 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
WO2020112781A1 (en) | 2018-11-28 | 2020-06-04 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
KR20210098488A (ko) | 2018-11-30 | 2021-08-10 | 브리스톨-마이어스 스큅 컴퍼니 | 글루타민-함유 경쇄 c-말단 연장부를 포함하는 항체, 그의 접합체, 및 방법 및 용도 |
WO2020123425A2 (en) | 2018-12-12 | 2020-06-18 | Bristol-Myers Squibb Company | Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses |
WO2021055306A1 (en) | 2019-09-16 | 2021-03-25 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6291673B1 (en) * | 1997-10-17 | 2001-09-18 | Purdue Research Foundation | Folic acid derivatives |
US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
US6291684B1 (en) * | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
JP2004532888A (ja) * | 2001-06-01 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | エポチロン誘導体 |
IL166039A0 (en) * | 2002-07-31 | 2006-01-15 | Schering Ag | New effector conjugates process for their production and their pharmaceutical use |
ES2395082T3 (es) * | 2003-01-27 | 2013-02-08 | Endocyte, Inc. | Conjugado de folato-vinblastina como medicamento |
JP2008515915A (ja) * | 2004-10-07 | 2008-05-15 | エモリー ユニバーシティー | 多機能性ナノ粒子結合体およびそれらの使用 |
-
2007
- 2007-05-24 PE PE2007000649A patent/PE20080102A1/es not_active Application Discontinuation
- 2007-05-24 AR ARP070102264A patent/AR062448A1/es not_active Application Discontinuation
- 2007-05-25 KR KR1020087031408A patent/KR20090025267A/ko not_active Application Discontinuation
- 2007-05-25 TW TW096118796A patent/TW200813065A/zh unknown
- 2007-05-25 JP JP2009512318A patent/JP2009538350A/ja not_active Withdrawn
- 2007-05-25 EA EA200802390A patent/EA200802390A1/ru unknown
- 2007-05-25 WO PCT/US2007/069740 patent/WO2007140298A1/en active Application Filing
- 2007-05-25 US US11/753,778 patent/US20070275904A1/en not_active Abandoned
- 2007-05-25 AU AU2007267536A patent/AU2007267536A1/en not_active Abandoned
- 2007-05-25 CA CA002657276A patent/CA2657276A1/en not_active Abandoned
- 2007-05-25 CN CNA2007800282294A patent/CN101495154A/zh active Pending
- 2007-05-25 MX MX2008014788A patent/MX2008014788A/es not_active Application Discontinuation
- 2007-05-25 EP EP07762328A patent/EP2023960A1/en not_active Withdrawn
- 2007-05-25 BR BRPI0712165-2A patent/BRPI0712165A2/pt not_active IP Right Cessation
-
2008
- 2008-11-11 IL IL195237A patent/IL195237A0/en unknown
- 2008-11-11 NO NO20084752A patent/NO20084752L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2009538350A (ja) | 2009-11-05 |
EP2023960A1 (en) | 2009-02-18 |
PE20080102A1 (es) | 2008-02-11 |
AR062448A1 (es) | 2008-11-12 |
IL195237A0 (en) | 2009-08-03 |
EA200802390A1 (ru) | 2009-06-30 |
TW200813065A (en) | 2008-03-16 |
BRPI0712165A2 (pt) | 2012-02-14 |
CA2657276A1 (en) | 2007-12-06 |
CN101495154A (zh) | 2009-07-29 |
AU2007267536A1 (en) | 2007-12-06 |
WO2007140298A1 (en) | 2007-12-06 |
MX2008014788A (es) | 2008-12-02 |
KR20090025267A (ko) | 2009-03-10 |
US20070275904A1 (en) | 2007-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084752L (no) | Konjugater av aziridinayl-epotilonanaloger og farmasoytiske sammensetninger som inneholder disse | |
NO20082088L (no) | Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer | |
NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
ECSP088871A (es) | Derivados de triazolopirazina | |
IL195030A (en) | IV dpp inhibitor assemblies | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
NO20091133L (no) | Anvendelse av 2-6-(3-amino-piperidin-L-yl)-3-metyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmetyl-4-fluor-benzonitril | |
TN2009000180A1 (en) | NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF | |
MX2011012122A (es) | Derivados de tiofeno. | |
NO20083726L (no) | Spiroindolinon derivater | |
NO20075113L (no) | Proteinkinaseinhibitorer | |
EA200970088A1 (ru) | Модуляторы метаболизма и лечение связанных с ним нарушений | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
WO2007135527A3 (en) | Benzimidazolyl compounds | |
TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
MY164646A (en) | Nicotine lozenge compositions | |
UA92000C2 (en) | 1-benzylindole-2-carboxamide derivatives | |
NO20085099L (no) | Puritonderivativer som HM74A agonister | |
MX2009011944A (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazo [4,5-b] piridin-5-amina y su uso para tratamiento de cancer. | |
MA32776B1 (fr) | Inhibiteurs de l'akt et de la p70 s6 kinase | |
BR112012011328A2 (pt) | inibidores de akt | |
MX2010013682A (es) | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. | |
NO20074933L (no) | Farmasoytisk sammensetning som innbefatter et indolylmaleimidderivat | |
NO20084826L (no) | Ny administrasjonsform av racecadotril | |
WO2008006795A3 (en) | Indole compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |